In our study, PD-L1-positive expression was associated with a lower VHL mutation frequency, which indicates that most VHL-mutated ccRCC patients might not receive benefit from anti-PD-1/L1 inhibitors combined with anti-VEGFR inhibitors. This evidence concerns the gene VHL and nonpapillary renal cell carcinoma.